<p>DiaMedica Therapeutics（納斯達克代碼：DMAC - 獲取免費報告）在週二發佈的報告中被華爾街 Zen 的投資分析師從 “持有” 評級下調至 “賣出” 評級。</p>
<p>其他股票研究分析師最近也對該股票發佈了研究報告。Craig Hallum 將 DiaMedica Therapeutics 的目標股價從 8.00 美元上調至 11.00 美元，並在 7 月 18 日的報告中給予該股票 “買入” 評級。HC Wainwright 在 8 月 15 日的報告中重申了 “買入” 評級，並對 DiaMedica Therapeutics 的目標股價設定為 12.00 美元。最後，Lake Street Capital 在 7 月 18 日的報告中將 DiaMedica Therapeutics 的目標股價從 11.00 美元上調至 14.00 美元，並給予該股票 “買入” 評級。根據 MarketBeat.com 的數據顯示，三位股票研究分析師給予該股票 “買入” 評級，公司共識評級為 “買入”，共識目標股價為 12.33 美元。</p>
<p>獲取 <strong>DiaMedica Therapeutics</strong> 的提醒：</p>
<p><strong>獲取我們最新的 DMAC 股票報告</strong></p>
<h2>DiaMedica Therapeutics 股票下跌 2.7%</h2>
<p>納斯達克 DMAC 的股票在週二以 5.71 美元開盤。DiaMedica Therapeutics 的 12 個月最低價為 3.19 美元，最高價為 6.82 美元。該股票的 50 日移動平均價格為 4.70 美元，200 日移動平均價格為 4.55 美元。公司的市值為 2.9515 億美元，市盈率為-8.28，貝塔值為 1.40。</p>
<p>DiaMedica Therapeutics（納斯達克代碼：DMAC - 獲取免費報告）最後一次公佈財報是在 8 月 12 日，報告顯示該公司本季度每股收益為（0.18 美元），符合分析師的共識預期（0.18 美元）。整體來看，研究分析師預計 DiaMedica Therapeutics 在當前財政年度將發佈-0.59 的每股收益。</p>
<h2>DiaMedica Therapeutics 的內部買賣</h2>
<p>在其他消息中，主要股東 Jan Stahlberg 在 7 月 23 日的交易中購買了 1,542,857 股該公司的股票。每股購買價格為 3.50 美元，總價值為 5,399,999.50 美元。收購完成後，該內部人士在公司持有 6,764,465 股，價值 23,675,627.50 美元。這筆交易代表了其持股比例的 29.55% 的增長。該收購在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司 7.30% 的股份。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者最近對 DMAC 的持倉進行了調整。Raymond James Financial Inc.在第四季度購買了 DiaMedica Therapeutics 的新頭寸，價值 83,000 美元。巴克萊銀行在第四季度購買了 DiaMedica Therapeutics 的新頭寸，價值 151,000 美元。Dimensional Fund Advisors LP 在第四季度將其在 DiaMedica Therapeutics 的持倉增加了 14.0%。Dimensional Fund Advisors LP 現在持有該公司 19,339 股股票，價值 105,000 美元，此前在上個季度又收購了 2,380 股。Susquehanna International Group LLP 在第四季度將其在 DiaMedica Therapeutics 的持倉增加了 269.5%。Susquehanna International Group LLP 現在持有該公司 374,845 股股票，價值 2,035,000 美元，此前在上個季度又收購了 273,395 股。最後，Northern Trust Corp 在第四季度將其在 DiaMedica Therapeutics 的持倉增加了 49.8%。Northern Trust Corp 現在持有該公司 180,192 股股票，價值 978,000 美元，此前在上個季度又收購了 59,902 股。機構投資者持有公司 10.12% 的股份。</p>
<h2>DiaMedica Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>DiaMedica Therapeutics Inc 是一家臨牀階段的生物製藥公司，專注於改善患有嚴重疾病的人的生活，重點是急性缺血性中風。其主要候選藥物是 DM199，一種藥理活性的重組人組織激肽酶-1 蛋白，目前正在進行急性缺血性中風的二期/三期臨牀試驗，同時也在進行二期臨牀試驗以治療心腎疾病。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 DiaMedica Therapeutics 更好</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>3 只具有長期順風的醫療保健先鋒</li>
<li>交易暫停的解釋</li>
<li>3 只免受關税影響的零售商創下新高</li>
<li>便士股票是否適合您的投資組合？</li>
<li>隨着股票接近高點，Broadcom 的第三季度報告值得關注</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 DiaMedica Therapeutics 嗎？</h2>
<p>在您考慮 DiaMedica Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 DiaMedica Therapeutics 並不在名單上。</p>
<p>雖然 DiaMedica Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DMAC

<p>華爾街禪將 DiaMedica Therapeutics（NASDAQ:DMAC）的評級從 “持有” 下調至 “賣出”。儘管如此，其他分析師仍給予該股票 “買入” 評級，目標價格範圍在 11.00 美元至 14.00 美元之間。該股票開盤價為 5.71 美元，下跌 2.7%，市值為 2.9515 億美元。主要股東 Jan Stahlberg 最近通過購買超過 150 萬股來增加其持股比例。機構投資者持有該公司 10.12% 的股份，該公司專注於急性缺血性中風和心腎疾病的治療</p>

<p>DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report issued on Tuesday.</p>
<div class="lb-trans"><p>DiaMedica Therapeutics（納斯達克代碼：DMAC - 獲取免費報告）在週二發佈的報告中被華爾街 Zen 的投資分析師從 “持有” 評級下調至 “賣出” 評級。</p>
</div><p>Other equities research analysts have also recently issued research reports about the stock. Craig Hallum lifted their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 18th. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Finally, Lake Street Capital lifted their price target on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 18th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of &#34;Buy&#34; and a consensus price target of $12.33.</p>
<div class="lb-trans"><p>其他股票研究分析師最近也對該股票發佈了研究報告。Craig Hallum 將 DiaMedica Therapeutics 的目標股價從 8.00 美元上調至 11.00 美元，並在 7 月 18 日的報告中給予該股票 “買入” 評級。HC Wainwright 在 8 月 15 日的報告中重申了 “買入” 評級，並對 DiaMedica Therapeutics 的目標股價設定為 12.00 美元。最後，Lake Street Capital 在 7 月 18 日的報告中將 DiaMedica Therapeutics 的目標股價從 11.00 美元上調至 14.00 美元，並給予該股票 “買入” 評級。根據 MarketBeat.com 的數據顯示，三位股票研究分析師給予該股票 “買入” 評級，公司共識評級為 “買入”，共識目標股價為 12.33 美元。</p>
</div><p>Get <strong>DiaMedica Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>DiaMedica Therapeutics</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Stock Report on DMAC</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 DMAC 股票報告</strong></p>
</div><h2>DiaMedica Therapeutics Stock Down 2.7%</h2>
<div class="lb-trans"><h2>DiaMedica Therapeutics 股票下跌 2.7%</h2>
</div><p>Shares of NASDAQ DMAC opened at $5.71 on Tuesday. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $6.82. The stock's 50 day moving average price is $4.70 and its 200-day moving average price is $4.55. The company has a market capitalization of $295.15 million, a PE ratio of -8.28 and a beta of 1.40.</p>
<div class="lb-trans"><p>納斯達克 DMAC 的股票在週二以 5.71 美元開盤。DiaMedica Therapeutics 的 12 個月最低價為 3.19 美元，最高價為 6.82 美元。該股票的 50 日移動平均價格為 4.70 美元，200 日移動平均價格為 4.55 美元。公司的市值為 2.9515 億美元，市盈率為-8.28，貝塔值為 1.40。</p>
</div><p>DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.18). As a group, research analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>DiaMedica Therapeutics（納斯達克代碼：DMAC - 獲取免費報告）最後一次公佈財報是在 8 月 12 日，報告顯示該公司本季度每股收益為（0.18 美元），符合分析師的共識預期（0.18 美元）。整體來看，研究分析師預計 DiaMedica Therapeutics 在當前財政年度將發佈-0.59 的每股收益。</p>
</div><h2>Insider Buying and Selling at DiaMedica Therapeutics</h2>
<div class="lb-trans"><h2>DiaMedica Therapeutics 的內部買賣</h2>
</div><p>In other news, major shareholder Jan Stahlberg purchased 1,542,857 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were purchased at an average price of $3.50 per share, with a total value of $5,399,999.50. Following the completion of the acquisition, the insider owned 6,764,465 shares in the company, valued at $23,675,627.50. This trade represents a 29.55% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，主要股東 Jan Stahlberg 在 7 月 23 日的交易中購買了 1,542,857 股該公司的股票。每股購買價格為 3.50 美元，總價值為 5,399,999.50 美元。收購完成後，該內部人士在公司持有 6,764,465 股，價值 23,675,627.50 美元。這筆交易代表了其持股比例的 29.55% 的增長。該收購在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司 7.30% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors have recently made changes to their positions in DMAC. Raymond James Financial Inc. bought a new position in shares of DiaMedica Therapeutics in the fourth quarter worth $83,000. Barclays PLC purchased a new position in DiaMedica Therapeutics in the fourth quarter worth $151,000. Dimensional Fund Advisors LP grew its position in DiaMedica Therapeutics by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company's stock worth $105,000 after acquiring an additional 2,380 shares in the last quarter. Susquehanna International Group LLP grew its position in DiaMedica Therapeutics by 269.5% in the fourth quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after acquiring an additional 273,395 shares in the last quarter. Finally, Northern Trust Corp grew its position in DiaMedica Therapeutics by 49.8% in the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after acquiring an additional 59,902 shares in the last quarter. Institutional investors own 10.12% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近對 DMAC 的持倉進行了調整。Raymond James Financial Inc.在第四季度購買了 DiaMedica Therapeutics 的新頭寸，價值 83,000 美元。巴克萊銀行在第四季度購買了 DiaMedica Therapeutics 的新頭寸，價值 151,000 美元。Dimensional Fund Advisors LP 在第四季度將其在 DiaMedica Therapeutics 的持倉增加了 14.0%。Dimensional Fund Advisors LP 現在持有該公司 19,339 股股票，價值 105,000 美元，此前在上個季度又收購了 2,380 股。Susquehanna International Group LLP 在第四季度將其在 DiaMedica Therapeutics 的持倉增加了 269.5%。Susquehanna International Group LLP 現在持有該公司 374,845 股股票，價值 2,035,000 美元，此前在上個季度又收購了 273,395 股。最後，Northern Trust Corp 在第四季度將其在 DiaMedica Therapeutics 的持倉增加了 49.8%。Northern Trust Corp 現在持有該公司 180,192 股股票，價值 978,000 美元，此前在上個季度又收購了 59,902 股。機構投資者持有公司 10.12% 的股份。</p>
</div><h2>DiaMedica Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>DiaMedica Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.</p>
<div class="lb-trans"><p>DiaMedica Therapeutics Inc 是一家臨牀階段的生物製藥公司，專注於改善患有嚴重疾病的人的生活，重點是急性缺血性中風。其主要候選藥物是 DM199，一種藥理活性的重組人組織激肽酶-1 蛋白，目前正在進行急性缺血性中風的二期/三期臨牀試驗，同時也在進行二期臨牀試驗以治療心腎疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than DiaMedica Therapeutics</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
<li>Trading Halts Explained</li>
<li>3 Tariff-Proof Retailers Making New All-time Highs</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 DiaMedica Therapeutics 更好</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>3 只具有長期順風的醫療保健先鋒</li>
<li>交易暫停的解釋</li>
<li>3 只免受關税影響的零售商創下新高</li>
<li>便士股票是否適合您的投資組合？</li>
<li>隨着股票接近高點，Broadcom 的第三季度報告值得關注</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DiaMedica Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 DiaMedica Therapeutics 嗎？</h2>
</div><p>Before you consider DiaMedica Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 DiaMedica Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 DiaMedica Therapeutics 並不在名單上。</p>
</div><p>While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 DiaMedica Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

華爾街禪將 DiaMedica Therapeutics（NASDAQ:DMAC）的評級下調至賣出